论文部分内容阅读
目的探讨基质金属蛋白酶-2(MMP-2)和趋化因子受体4(CXCR4)在肾透明细胞癌组织中的表达及其与临床病理因素的关系。方法应用免疫组化PV6000法检测79例肾透明细胞癌(RCCC)组织和43例正常肾组织中MMP-2和CXCR4的表达。结果 79例RCCC中MMP-2和CXCR4的阳性表达率为73.4%、77.2%,高于在正常肾组织中的阳性表达率(16.3%,14.0%),差异有统计学意义(χ2=36.520、45.009,P<0.01),其表达与RCCC的临床分期和淋巴结转移有关(χ2=3.978～5.657,P<0.05)。MMP-2和CXCR4的表达呈正相关(r=0.561,P<0.01)。结论 MMP-2和CXCR4在肾透明细胞癌组织中呈高表达,其与肿瘤的发生、发展、转移及临床病理参数之间有相关性,可能在肿瘤的进展过程中扮演重要角色。
Objective To investigate the expression of matrix metalloproteinase-2 (MMP-2) and chemokine receptor 4 (CXCR4) in renal clear cell carcinoma and its relationship with clinicopathological factors. Methods The expression of MMP-2 and CXCR4 in 79 cases of renal clear cell carcinoma (RCCC) and 43 cases of normal renal tissues were detected by immunohistochemistry PV6000. Results The positive expression rates of MMP-2 and CXCR4 in 79 cases of RCCC were 73.4% and 77.2%, respectively, which were higher than those in normal renal tissues (16.3% and 14.0%, respectively) (χ2 = 36.520, 45.009, P <0.01). The expression was related to the clinical stage and lymph node metastasis of RCCC (χ2 = 3.978-5.657, P <0.05). The expression of MMP-2 and CXCR4 was positively correlated (r = 0.561, P <0.01). Conclusions MMP-2 and CXCR4 are highly expressed in clear cell renal cell carcinoma, which is correlated with the occurrence, development, metastasis and clinicopathological parameters of the tumor, which may play an important role in the progression of the tumor.